BOSTON, January 22, 2026 — Delve Bio announced new clinical evidence demonstrating that earlier use of metagenomic next-generation sequencing (mNGS) can significantly reduce diagnostic testing burden, shorten time to diagnosis, and lower healthcare costs for patients with meningitis and encephalitis (M/E). Data published in Open Forum Infectious Diseases show that deploying comprehensive mNGS testing shortly after the first lumbar puncture enables faster pathogen identification within 48 hours, streamlining clinical decision-making in complex central nervous system (CNS) infections.
Science Significance
From a scientific perspective, the findings reinforce the value of unbiased, pathogen-agnostic mNGS in diagnosing CNS diseases where traditional testing often fails to identify a cause. By detecting both RNA and DNA pathogens in a single assay, Delve Bio’s Delve Detect overcomes limitations of sequential microbiological tests that can delay diagnosis. The study modeled real-world clinical scenarios and demonstrated that up to 64% of microbiological tests in infectious M/E and 92% in autoimmune encephalitis could be avoided when mNGS is used earlier. These results highlight how systems-level diagnostic innovation can transform infectious disease workflows by replacing fragmented testing with a comprehensive molecular approach.
Regulatory Significance
The study’s conclusions have important regulatory implications for clinical laboratory practice and diagnostic stewardship. Early deployment of mNGS aligns with evolving expectations for evidence-based diagnostic algorithms under regulated laboratory frameworks. By reducing unnecessary testing and invasive procedures, earlier mNGS use supports quality-driven clinical pathways consistent with GxP principles, particularly Good Clinical Practice and CLIA-aligned laboratory operations. The structured modeling approach used in the study also provides a data-driven foundation for institutions evaluating validation, utilization, and implementation strategies for advanced molecular diagnostics in CNS infections.
Business Significance
Advertisement
For healthcare institutions, the analysis underscores the economic impact of early diagnostic clarity. Shortening time to diagnosis by nearly seven days per patient in infectious M/E and more than ten days in autoimmune encephalitis translates into reduced hospital stays, fewer repeat procedures, and lower overall costs. For Delve Bio, the data strengthen the value proposition of Delve Detect as a high-impact clinical service, supported by rapid turnaround times and access to a Clinical Microbial Sequencing Board for expert interpretation. The results position mNGS not only as a scientific advance, but also as a cost-effective diagnostic strategy in high-acuity care settings.
Patients’ Significance
For patients, especially those facing life-threatening CNS conditions, time to accurate diagnosis is critical. Delays in identifying infectious versus autoimmune causes of encephalitis can lead to prolonged uncertainty, inappropriate therapies, and increased morbidity. The study shows that earlier mNGS testing can reduce repeated lumbar punctures and extensive diagnostic workups, enabling faster initiation of targeted treatment or immunotherapy. By minimizing diagnostic delays, early mNGS use has the potential to improve outcomes, reduce complications, and ease the physical and emotional burden on patients and families during prolonged hospitalizations.
Policy Significance
At a policy level, the findings support broader healthcare objectives focused on diagnostic efficiency, antimicrobial stewardship, and value-based care. Evidence that early mNGS use can reduce unnecessary testing and hospital length of stay aligns with payer and institutional goals to optimize resource utilization without compromising care quality. As healthcare systems increasingly emphasize outcomes-driven reimbursement and precision diagnostics, studies like this provide critical support for policy discussions around adoption, coverage, and standardized use of advanced molecular testing in complex infectious diseases.
Overall, the study adds to growing evidence that earlier integration of metagenomic sequencing into clinical workflows can meaningfully improve care for patients with meningitis and encephalitis. By demonstrating reductions in diagnostic complexity, time to diagnosis, and institutional burden, Delve Bio’s findings highlight how advanced diagnostics can drive both clinical excellence and operational efficiency. As healthcare systems seek faster, more precise answers in critical infections, early mNGS testing is emerging as a clinically and economically transformative tool.
Source: Delve Bio press release
